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Distinct subtypes of ADTKD-REN in an international cohort study 






There have been few clinical or scientific reports of autosomal dominant tubulo-interstitial kidney 2 
disease due to REN mutations (ADTKD-REN), limiting characterization.  We formed an international 3 
cohort that characterized 111 individuals from 30 families both clinically and in the laboratory.  Sixty-4 
nine (62%) individuals had a REN mutation in the signal peptide region (signal group), 27 (24%) in the 5 
prosegment (prosegment group), and 15 (14%) in the mature renin peptide (mature group).  Signal 6 
group patients were most severely affected, presenting at a mean age of 19.7±15.7 years, with the 7 
prosegment group presenting at 22.4±20.2 years, and the mature group at 37±12.4 years. Anemia was 8 
present in childhood in 91% in the signal group, 69% prosegment, and 0 of the mature group.  REN signal 9 
peptide mutations reduced the signal peptide’s hydrophobicity, which is necessary for recognition and 10 
translocation across the endoplasmic reticulum (ER) membrane, leading to aberrant delivery of 11 
preprorenin into the cytoplasm. REN mutations in the prorenin segment led to deposition of prorenin 12 
and renin in the endoplasmic reticulum Golgi intermediate compartment (ERGIC) and decreased 13 
prorenin secretion. Mutations in mature renin led to deposition of the mutant prorenin in the 14 
endoplasmic reticulum, similar to patients with ADTKD-UMOD, with a rate of progression to ESKD 15 
(63.6±7.6 y) that was significantly slower vs. the signal (50.8±17.6 y)  and prosegment groups (53.1±10.6 16 
years) (hazard ratio 0.367, p=0.023). Clinical and laboratory studies revealed subtypes of ADTKD-REN 17 
that are pathophysiologically, diagnostically, and clinically distinct. 18 
 19 
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Autosomal dominant tubulo-interstitial kidney disease (ADTKD) is characterized by autosomal dominant 25 
inheritance, bland urinary sediment, and slowly progressive chronic kidney disease (CKD) leading to end-26 
stage kidney disease (ESKD) between 30 and 80 years (1).  While ADTKD was described in fewer than 10 27 
families prior to 1990, genetic testing has led to increased detection, with over 300 families reported (2-28 
5).  ADTKD due to mutations in the REN gene encoding renin (ADTKD-REN) is one of the least common 29 
forms of ADTKD (5), with only 8 families and 28 individuals reported before 2020 (5-11).  30 
Renin is a hormone primarily produced in the kidney that is requisite for tubulogenesis (12) and 31 
embryonic kidney formation (13). The renin angiotensin system (RAS) is a key modulator of blood 32 
pressure (14) and CKD progression (15). Renin biosynthesis constitutes the first enzymatic steps in the 33 
RAS. The human renin precursor is synthesized in the juxtaglomerular cells of the macula densa as a 406 34 
amino acid preprorenin, composed of a 23 amino acid N-terminal signal peptide, a 43 amino acid 35 
prosegment, and a 340 amino acid mature renin peptide (16). During biosynthesis, the signal peptide 36 
mediates insertion of the nascent preprorenin into the translocation channel in the endoplasmic 37 
reticulum (ER) and initiates cotranslational translocation of preprorenin into the ER lumen, where 38 
glycosylation and proteolytic processing of the nascent preprorenin occur, conditioning further transit of 39 
prorenin and renin through the constitutive and regulated secretory pathways (17).  40 
In ADTKD-REN, heterozygous REN mutations lead to decreased synthesis of prorenin and renin, 41 
resulting in mild hyperkalemia, anemia, hyperuricemia, and a predisposition to the development of 42 
acute kidney injury (5).  REN mutations have been reported in the segment of the REN gene encoding 43 
the signal peptide (5-8) and the mature renin protein (9, 10). Mutations in the prosegment – a segment 44 
of the gene after the signal peptide that assists in protein folding – have not been reported. The small 45 
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number of case reports of ADTKD-REN has prevented clinical correlation with mutation type and 46 
identification of risk factors for progression to ESKD. 47 
We performed an international retrospective cohort study and collected clinical and genetic 48 
data on 111 individuals from 30 families with heterozygous REN mutations in order to better 49 
characterize this condition.  We performed laboratory investigations on ten representative mutations 50 
(five in the signal peptide, three in the prosegment, and two in mature renin) and characterized two 51 
missense REN variants of unknown significance found in African-Americans, p.P8A and p.R33W. 52 
RESULTS 53 
Of 111 individuals from 30 families (see Table 1 and Supplementary Figures S1, S2), sixty-nine (62%) 54 
individuals had a mutation in the signal peptide, 27 (24%) in the prosegment, and 15 (14%) in the 55 
mature renin peptide.  A mutation in p.S45N was identified in one individual with ADTKD of unknown 56 
cause.  This mutation did not segregate with disease and was determined to be nonpathogenic; it was 57 
included as a control for laboratory investigations. While searching variant databases, we noticed two 58 
additional rare missense variants (AA_REN variants) found specifically in African-Americans, a group 59 
with an increased prevalence of low-renin hypertension and CKD (18). These variants encode p.P8A in 60 
the signal peptide and p.R33W in the prosegment of preprorenin. Their allelic frequencies in African-61 
Americans are 0.007 and 0.001 respectively. 62 
Effect of Mutation Class on Clinical Characteristics 63 
Presentation 64 
After excluding patients with missing data (n=14) and those identified by genetic screening (n=16), there 65 
were 81 patients for analysis (see Table 2).  Patients in the signal group were the most severely affected 66 
and presented at the youngest age.  The mean age of clinical presentation was 19.7±15.7 years for the 67 
signal group, 22.4±20.2 years for the prosegment group, and 37.0±12.4 years for the mature group 68 
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(p<0.001 for comparison of the mature group vs. signal and prosegment group).  Only patients in the 69 
signal group presented with acute kidney injury (10%) or acidosis, anemia, and kidney failure (13%).  70 
Thirty-one percent of patients in the signal group and 50% of patients in the prosegment group 71 
presented with anemia.  Patients in the mature group presented only with gout (75%) or CKD (25%).  72 
The mean age of presentation was similar for men and women (19.3±13.7 years vs. 19.9±19.4 years, 73 
p=0.6).   74 
Kidney function 75 
Kidney function was less severely affected in the mature group vs. the signal and prosegment groups.  76 
Figure 1A displays all estimated glomerular filtration (eGFR) values obtained for the entire cohort of 77 
patients.  An eGFR of 10 mL/min/1.73m
2
 was assigned at the age of ESKD.  Patients in the signal and 78 
prosegment group presented much earlier in life.  At earliest clinical presentation, the majority of eGFR 79 
readings in these groups were below 60 mL/min/1.73 m
2
, suggesting that decreased kidney function is 80 
present at birth in most patients.  Despite early decreased function, eGFR values tended to remain 81 
relatively stable during childhood and through adolescence.  Figure 1B shows data on 13 children in the 82 
signal group with multiple eGFR measurements.  In almost all cases, eGFR remained steady with minimal 83 
decline, including one patient whose eGFR remained stable at approximately 30 mL/min/1.73m
2
 from 84 
age 2 through age 16 (Figure 1B: p.C20R with red markers).  Another patient (p.M39K) presented during 85 
infancy with an eGFR of 19 mL/min/1.73 m
2
 and had a relatively stable eGFR through childhood before 86 
proceeding to renal replacement therapy at 15 years, being the only individual reaching ESKD prior to 87 
age 30 years. After adolescence, there was in general a slow decline in eGFR in the signal and 88 
prosegment groups (see Figure 1A). The median age of ESKD was 57 years in the signal group, 62 years 89 
in the prosegment group, and 68 years in the mature group (Figure 2).  Patients in the mature group had 90 
no laboratory values until age 20 years, due to milder manifestations (see Figure 1A).  Patients in the 91 
mature group presenting at this age appeared to have normal kidney function.   92 
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To evaluate risk factors for ESKD progression, univariate Cox proportional hazards models were 93 
created, with the event being age of ESKD.  Patients in the mature group had a significantly decreased 94 
risk of developing ESKD over time vs the signal and prosegment groups combined, with a hazard ratio of 95 
0.37 (p=0.023) (See Table 3 and Figure 2).  In other univariate models, anemia in childhood (hazard ratio 96 
2.82, p=0.03) (See Table 3 and Figure 3) was significantly associated with an earlier age of ESKD, while 97 
gender was not associated with progression to ESKD. The best-fit Cox proportional hazards model 98 
included only anemia in childhood (See Table 3 and Figure 3).   99 
Anemia 100 
 Figure 4A shows hemoglobin levels in patients not on erythropoietin. The lowest hemoglobin values 101 
were 7.5 g/dL.  The mean hemoglobin level was 9.6±1.04 g/dL for age <10 years, 10.1±1.1 g/dL for 10 to 102 
<15 years, and 10.5±1.2 g/dL for ages 15 to < 20y. Females were more likely to have anemia as a child 103 
(97% vs. 46%, p=0.005) and have lower hemoglobin levels (see Table 4 and Figure 4A). Hemoglobin 104 
levels in women tended to remain low over time, while in men, hemoglobin levels appeared to rise after 105 
age 20 years.  For 14 children who never received erythropoietin, the mean hemoglobin level was 106 
9.8±1.2 g/dL (range 7.4-13.8 g/dL).  For children who received erythropoietin, while not receiving 107 
erythropoietin the mean hemoglobin level was 10.1±1.3 g/dL (range 7.6-12.6 g/dL). 108 
Hyperkalemia and academia 109 
Hyperkalemia was present but rarely reach life-threatening levels. Figure 4 shows serum potassium 110 
according to age (4B) and eGFR (4C).  Serum bicarbonate levels vs. age are depicted in Figure 4D.  Serum 111 
bicarbonate values were frequently below 24 mEq/L.   112 
Gout 113 
In individuals not taking allopurinol or febuxostat, males had a higher serum urate level than women 114 
(9.4±2.7 mg/dl vs. 7.7±1.6 mg/dl, p=0.02) and were more likely to have gout (49.3% vs. 39.5%, p<0.01). 115 
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Renin levels 116 
Plasma renin levels were low, with the mean random plasma renin activity (normal range 2.9 to 24 117 
ng/mL/h) in the signal group 0.5±0.8 ng/ml/h (n=18), in the prosegment group 0.5±0.6 ng/ml/h (n=4), 118 
and in the mature group 0.8±0.7 ng/ml/h (n=5).   119 
Fludrocortisone 120 
Fludrocortisone was administered to two patients consistently and in seven patients for a short period 121 
of time.  There were no adverse effects from fludrocortisone.  In one patient, it was taken consistently 122 
from age 11 onwards, and in another patient from age 13 (Figure 5).  The serum potassium values were 123 
lower in nine individuals while taking vs. not taking fludrocortisone (4.37±0.54 mEq/L vs 4.77±0.55 124 
mEq/L, p< 0.01).   The serum bicarbonate values were also higher (25.9±2.3 mEq/L vs. 23.7±3.5 mEq/L, 125 
p=0.003).   126 
In silico analysis 127 
 Figure 6A displays the REN mutations identified in ADTKD families. Except for the p.T26I and the non-128 
pathogenic p.S45N, all amino acid residues at mutation sites are absolutely conserved across species 129 
(Figure 6B). SignalP 4.1 prediction software (19) indicates that all signal peptide mutations except 130 
p.C20R decrease the cleavage site prediction scores (C-score) (Figure 6C), suggesting a decrease in the 131 
efficacy of the signal peptidase mediated release of the signal peptide from preprorenin. Scores for the 132 
AA_REN p.P8A variant are similar to wild type (Figure 6C).The mutations in the prosegment, including 133 
the AA_REN variant p.R33W, are classified by the M-CAP pathogenicity classifier (20) as either likely 134 
benign (p.T26I, p.M39K and p.S45N (non-pathogenic)) or possibly pathogenic (p.R33W). Mutations in 135 
mature renin (p.C325R, p.I366N) are classified as possibly pathogenic (Figure 6D).  136 
All mutations have significant effects on prorenin structure (Figure 7) and may modulate renin activity 137 
by affecting the folding, constitutive secretion and proteolytic processing of prorenin (21-23).  138 
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Functional studies of identified REN variants 139 
Wild type and mutant proteins were transiently expressed in HEK293 cells (Figure 8). Western blot and 140 
immuno-detection of corresponding proteins showed that the wild type protein was present in the cell 141 
lysate in three major forms (Figure 8A) corresponding to preprorenin (45 kDa), prorenin (47 kDa) and 142 
renin (43 kDa), with the preprorenin being less abundant. In the culture media (Figure 8B), only prorenin 143 
was detected. Proteins with mutations in the signal peptide were present in cell lysates mostly in the 144 
form of preprorenin, with no prorenin or renin detected in culture media. Proteins with mutations 145 
p.T26I and p.M39K in the prosegment were present in cell lysates in all three forms similar to the wild 146 
type protein, whereas the nonpathogenic p.S45N was present mostly in the form of prorenin. 147 
Prosegment mutations affected secretion of p.M39K prorenin into culture media; however, secretion of 148 
p.T26I and p.S45N was unaffected. Proteins with mutations in the mature renin were present in cell 149 
lysate predominantly as prorenin and were not secreted into culture media. Proteins with AA_REN 150 
variants in the signal peptide (p.P8A) or prosegment (p.R33W), showed similar profiles to wild type 151 
protein in cell lysates. The mutation p.R33W affected secretion of prorenin into culture media (Figure 152 
8A,B). Quantitative immunoradiometric assay (Figure 8E,F) showed that mutations in the signal peptide 153 
either significantly reduced (p.L16del) or entirely prevented renin and prorenin synthesis in cells and 154 
their secretion into culture media. Mutations in the prosegment had either no effect or a marginal effect 155 
(p.M39K) on renin and prorenin synthesis, but affected secretion of p.T26I and p.M39K into culture 156 
media. Secretion of nonpathogenic p.S45N was unaffected. Mutations in the mature renin led to the 157 
synthesis of prorenin and renin that were either inactive or undetectable by the antibody used in the 158 
assay. The AA_REN variant p.P8A had no effect on renin and prorenin synthesis in cells and secretion of 159 
prorenin and renin into the culture media. For the AA_REN variant p.R33W, there was reduced secretion 160 
of prorenin into the culture media (Figure 8C, D). Proteolytic activity assay showed that mutations in the 161 
signal peptide either reduced (p.L16del) or entirely abolished renin activity in culture media. Mutations 162 
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in the prosegment led either to a production of proteolytically “hyperactive” prorenin (p.M39K) or 163 
reduced the activity of renin in the culture media (p.T26I, p.S45N). Mutations in the mature renin 164 
abolished production of active renin. The AA_REN variant p.P8A had no effect on the proteolytic activity 165 
of secreted renin and prorenin. The AA_REN variant p.R33W reduced renin activity via low prorenin 166 
secretion (Figure 8E, F). Mutated proteins had altered intracellular localization (Figure 9A). Wild type 167 
protein was present in coarsely granular structures that were localized in the cytoplasm and in the 168 
LAMP2 positive lysosomal-like structures. Proteins with signal peptide mutations demonstrated mostly 169 
diffuse cytoplasmic staining. Proteins with prosegment mutations were localized mainly to endoplasmic 170 
reticulum intermediate compartment (ERGIC). Proteins with mutations in the mature renin formed 171 
intracellular clumps localized in the ER (Figures 9A,B, Supplementary Figure S3). There was little renin 172 
staining in the Golgi apparatus for wild-type and REN mutations (Supplementary Figure S4). Wild type 173 
protein and proteins with prosegment mutations were localized in lysosomes whereas proteins with 174 
signal peptide mutations (except of p.L16del) and proteins with mutations in the mature renin were not 175 
(Supplementary Figure S5). All functional data are summarized in Table 5. 176 
DISCUSSION 177 
In this work we describe distinct clinical and pathophysiologic differences (Figure 10) in signal, 178 
prosegment, and mature peptide mutations of the REN gene in a cohort of 111 patients from 30 families 179 
with ADTKD-REN. 180 
Patients with mutations in the signal peptide region were the most severely affected.  One-third 181 
presented before age 10, with 10% having acute kidney injury and 13% presenting with anemia, acidosis, 182 
and kidney failure.  The mean age of presentation was lower than in the other two groups (19.7±15.7 183 
years vs. 22.4±20.2 years and 37.0±12.4 years).  We demonstrated that transiently expressed proteins 184 
with mutations in the signal peptide lead to proteosynthesis of preprorenin that, according to 185 
13 
 
immunofluorescence studies, is probably located in the cytoplasm or faces the cytoplasmic side of the 186 
ER or ERGIC membranes. This phenomena has previously been described in a case of signal peptide 187 
mutations of preproinsulin leading to β cell failure and autosomal dominant diabetes (24, 25) and in a 188 
mutation in the preproparathyroid hormone (PTH) gene resulting in familial isolated 189 
hypoparathyroidism (26). The effects of aberrant renin production not only resulted in manifestations of 190 
clinical renin deficiency but likely also affected normal renal embryogenesis, resulting in decreased 191 
kidney function at birth. The presence of significantly decreased renin activity in the setting of a 192 
heterozygous mutation is likely due to the mutated protein blocking the translocon and affecting 193 
synthesis of functional renin from the wild-type allele, a phenomenon that has been observed in ADTKD 194 
caused by mutations of Translocon Subunit Alpha 1 (SEC61A1) (4) or in preproinsulin signal peptide 195 
mutations, resulting in permanent neonatal diabetes, despite the presence of a wild-type insulin allele 196 
(27). 197 
61% of individuals in the prosegment group presented at less than 10 years (61%), often 198 
presenting with gout (36%) and anemia (50%). The prosegment (propeptide) is a structural element that 199 
determines the biosynthesis, cellular trafficking and function of most proteases (28), including prorenin 200 
(21-23). Mutations in the prosegment leading to dominant phenotypes have been reported in several 201 
other preproteins, including proinsulin (leading to diabetes) (29) and factor IX deficiency (haemophilia) 202 
(30). The prosegment mutations in prorenin described here are classified as likely benign by various 203 
pathogenicity prediction programmes. However, based on structural studies, they are predicted to 204 
change interactions of the prosegment region with renin that are critical for the maintenance of the 205 
protease in its inactive state [24]. Accordingly, we demonstrated that mutations in the prosegment do 206 
not significantly affect the amounts of synthesized prorenin and renin, but rather they alter secretion 207 
and enzyme activity regulating properties of the prosegment as demonstrated by altered proportions of 208 
synthesized, enzymatically active renin and prorenin (Table 5). This altered proportion may also reflect 209 
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the effect of prosegment mutations on trafficking through the intracellular vesicular network, within 210 
which processing of prorenin to renin occurs. Such an effect is suggested by specific accumulation of 211 
proteins with prosegment mutations (compared to other REN mutations) in the ER-Golgi intermediate 212 
compartment (ERGIC), where the quality control system of the early secretory pathway and the 213 
concentration process of nascent secretory proteins into secretory granules take place (31). The age of 214 
presentation and severity of prosegment mutations may vary significantly due to the type of mutation 215 
and its specific effects on biosynthesis, cellular trafficking and proteolytic processing of prorenin and 216 
renin activity regulation. In addition to causing cellular toxicity, these dominant negative effects may be 217 
due to abnormal interactions between the mutant and wild-type proteins that are being processed in 218 
parallel, as seen in early onset insulin-deficient diabetes (32). The non-pathogenic p.S45N variant 219 
showed normal in vitro scores and normal (actually increased) enzyme activity. Accumulation in the 220 
ERGIC however suggests that the p.S45N mutation affects protein trafficking and could potentially lead 221 
to late-onset CKD. 222 
Mutations in the genetic region encoding the mature renin peptide had a much milder course 223 
compared to patients with mutations in the region encoding the signal peptide or preprorenin, as first 224 
noted by Schaeffer in a case report of a family with the p.L381P REN mutation (11).  In contrast to 225 
patients in the signal and prosegment group who often present in childhood, patients in the mature 226 
group first present in their twenties with gout or present later in life with unexplained CKD. These 227 
patients appear to have normal kidney function early in life. Whether individuals in the mature group 228 
had anemia in childhood is unclear, but if present it was asymptomatic in the patients in our cohort.  229 
Two mutations in mature renin were studied in vitro. These mutations destabilize renin structure and 230 
produce an enzymatically inactive prorenin that is trapped within the ER, similar to the mature REN 231 
mutation p.L381P (11). The localization of the mutated mature renin protein and pathophysiologic 232 
changes are very similar to changes found in ADTKD due to UMOD mutations, and the two conditions 233 
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are quite similar clinically. Better clinical outcomes in the mature group may be  due to decreased 234 
cellular toxicity of the mature renin mutations and decreased effects on cellular processing of the wild-235 
type renin produced by the normal allele, similar to mutations in the mature insulin peptide found in 236 
diabetes mellitus, with onset of symptoms in adulthood (33-35). 237 
REN mutations identified in African-Americans 238 
We also evaluated two missense REN variants of unknown significance, p.P8A and p.R33W, which are 239 
located in the signal peptide and prosegment of preprorenin and are present in relatively high 240 
frequencies in African-Americans. Individuals of African descent show a higher prevalence of low renin 241 
hypertension and ESKD (18), and we were interested to evaluate their functional impact. Our analyses 242 
demonstrated that whereas the p.P8A variant has no effect, the p.R33W variant has altered properties 243 
that are very similar to other ADTKD-REN prosegment mutations. With population frequencies of 0.001 244 
the p.R33W may thus represent a genetic factor contributing to heritability of low circulating plasma 245 
renin and CKD in a small group of African-Americans. We were unable to recruit and study any 246 
individuals with the p.R33W mutation, who could have mild hyperkalemia, gout, and CKD with aging.  247 
While this is the largest study of patients with ADTKD-REN, the small number of participants still 248 
limited our ability to assess the effects of fludrocortisone. Moreover, data was limited in teenage males 249 
and patients in the mature group. As the study was retrospective and these individuals were 250 
asymptomatic, there was no need for clinicians to perform laboratory studies earlier in life. We are 251 
interested in adding further families to our registry in order to improve clinical characterization, and we 252 
would appreciate information on other families with this disorder (please contact 253 
ableyer@wakehealth.edu). 254 
In summary, families with ADTKD-REN can be divided into three groups.  Patients with 255 
mutations in the region encoding the mature peptide present with gout in early adulthood or CKD later 256 
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in life. Their course is milder than in patients with mutations in the regions encoding the signal peptide 257 
and prosegment. In these latter two groups, kidney function appears to be decreased starting from birth 258 
in many patients but remains stable through early adulthood. Anemia, hyperkalemia, and acidosis are 259 
frequently present, with acidosis being inadequately treated in a number of patients.  Fludrocortisone 260 
raises eGFR, lowers serum potassium, and improves serum bicarbonate, but only a few patients received 261 
treatment with this medication, limiting our abilities to understand advantages and disadvantages of 262 
treatment. 263 
METHODS 264 
This investigation was approved by the institutional review boards of the participating centers and was 265 
carried out in accordance with the Declaration of Helsinki.   266 
Identification of cases 267 
Between January 1, 2019 and February 29, 2020, the literature was reviewed for families reported with 268 
heterozygous REN mutations, and the authors were contacted for additional information regarding 269 
affected patients.  Academic centers with an interest in ADTKD were contacted and asked to provide 270 
clinical and genetic data from families with ADTKD-REN that had not been reported (Supplementary 271 
Figure S1). Investigators were asked to provide the following information for each individual from birth 272 
through February 29, 2020: mutation, age and reason for presentation, all hemoglobin values and use of 273 
erythropoietin, all serum electrolyte, uric acid, blood urea nitrogen and creatinine values, the age of 274 
onset of ESKD, and the use of fludrocortisone, allopurinol, or alkali supplementation. These mutations 275 
were not present in the Genome Aggregation Database (36) and segregated with disease in affected 276 
families, with the exception of p.S45N, which was found not to segregate with disease in the one family 277 
found to have this mutation. 278 
Genetic evaluation 279 
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REN mutations were identified using either Sanger sequencing of individual REN exons, panel 280 
sequencing or whole exome sequencing essentially as described (4, 5).  281 
Calculation of estimated glomerular filtration rate 282 
The estimated glomerular filtration rate (eGFR) was determined using the Pottel equation (37). This 283 
equation takes into account age, gender, and serum creatinine values.  It was specifically chosen 284 
because it has been shown to be accurate in all age groups and allows for a continued comparison of 285 
data from childhood into adulthood (37), a critical period of analysis in this cohort. 286 
Statistical analysis 287 
Statistical analysis was carried out using SAS statistical software (Cary, NC), using standard analytical 288 
tests such as the T-test, Chi-squared test, multivariate regression, and Cox proportional hazards 289 
regression.  For comparison of laboratory values (including serum potassium, uric acid, hemoglobin, and 290 
bicarbonate), the mean values for each patient were determined and compared with the mean values of 291 
other patients.  This analysis was chosen to maximize the use of data while also controlling for an 292 
increased number of measurements for some individuals. 293 
In silico analysis 294 
Properties of the signal sequences were assessed as described (5, 6). Mutations were mapped into the 295 
prorenin structure (PDB ID 3VCM). Structural models were visualized using Pymol Viewer (DeLano 296 
Scientific Palo Alto, CA, USA). 297 
Transient expression of preprorenin in HEK293 cells  298 
Wild type REN cloned into pCR3.1 a eukaryotic expression vector was used and corresponding mutated 299 
constructs were prepared by site-directed mutagenesis as in our previous study (5, 6). Transfection, 300 
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qualitative and quantitative assays and immunofluorescence analysis of renin were performed as 301 
described in (5, 6) and in Supplementary methods. 302 
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Table 1.  Distribution of heterozygous mutations causing ADTKD-REN mutations by mutation group 
and family.  
Mutation group Mutation Families (n) Individuals (n) 
Signal p.W10R 1 5 
 p.L12P 1 1 
 p.L13Q 1 1 
 p.delL16 6 28 
 p.L16P 3 11 
 p.L16R 2 9 
 p.W17R 4 9 
 p.C20R 3 5 
Signal total  21 69 
    
Prosegment p.T26I 2 19 
 p.M39K 1 5 
 p.E48K 1 3 
Prosegment total  4 27 
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Mature p.C325R 1 3 
 p.I366N 1 2 
 p.L381P 1 5 
 p.T391R 1 4 
 p.Q85H 1 1 
Mature Total  5 15 





Table 2. Characteristics according to mutation group. 
 Signal Prosegment Mature P value 
Individuals 69 (62%) 27(24%) 15(14%)  




 < 10 




 10 to 
< 20 


















   0.014 
      Acute kidney 
       injury 
5/55 (10%) 0 0  
       Anemia,    
       acidosis, kidney 
7/55(13%) 0 0  
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       failure 
      Anemia 17/55(31%)  7/14(50%) 0  
      Chronic kidney  
      disease 
12/55(22%) 2/14(14%) 3/12(25%)  
      Gout 14/55(25%) 5/14(36%)  9/12(75%)  
Total 55 14 12  
Anemia as child (%) 39/43(91%) 11/16(69%) 0/7(0%) <0.001 
Gout developed 
during the course 
of disease  (%) 
31/55(56%) 13/20(65%) 9/14(64%) 0.74 
Age at first gout 
attack (mean±s.d.) 
29.7±9.9 25.7±8.2 32.9±11.2 0.4 






Excluding individuals who presented for asymptomatic genetic screening. Six of 61 (10%) in the signal 
group, 7/21 (33%) in the prosegment group, and 3/15 (20%) patients in the mature group were 
identified by asymptomatic genetic screening. 
2




Table 3.  Proportional hazards models including all individuals, with the event being age of end-stage 
kidney disease (ESKD).  The univariate model showing anemia in childhood was also the best-fit 
multivariate model. 
Model Risk Reference Hazard ratio P value 









Univariate  Anemia in 
childhood 









Table 4. Characteristics of presentation according to gender for patients with signal peptide or 
prosegment mutations. 
 Female Male P value 
Individuals 44 52 0.41 
Age at presentation
1
 < 10 18/35(48.6%) 17/43(39.5) 0.42 
Age at presentation
1
 10 to < 
20 
 9/35(25.7%) 12/43(27.9%) 0.85 
Age at presentation
1
 >20  9/35(25.7) 13/43(30.2%) 0.66 
Age at presentation 
(mean±s.d.) 
19.9±19.4 19.3±13.7 0.6 
Anemia as child (%) 31/32(96.7%) 19/27(45.8%) 0.005 
Gout (%) 15/38(39.5%) 29/37(49.3%) 0.0006 
Age at first gout attack 
(mean±s.d.) 
30.3±9.6 27.8±9.7 0.45 
Age at ESKD onset 
(mean±s.d.) 
50.1±11.4 55.8±10.5 0.25 
Serum potassium (mEq/L) 
(mean±s.d.) 
5.1±0.5 5.1±0.6 0.75 
Serum bicarbonate (mEq/L) 
(mean±s.d.) 
21.3±0.4 22.2±2.5 0.38 
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Serum urate (mg/dL) without 
urate-lowering therapy 
(mean±s.d.) 
7.7±1.6 9.4±2.7 0.02 
1
Excluding individuals who presented for asymptomatic genetic screening.  
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Table 5 REN mutations; a summary of in vitro characteristics 





































% of wild 
type  renin 
Renin  
activity 








288-317 antibody detecting 












+ - 705±71 100±4 7.5 100±6 100±4 1 
Coarsely granular structures  











+ - 457±41 61±1 7.5 27±1 21±3 1.3 
Less distinct granular 





























+ - 167±19 130±11 1.3 87 72 1.2 
Less distinct  granular 
structures in cytoplasm and 
lysosomes with diffuse 











































- - 0 0 0 0.1±0.1 0 0 
Intracellular clumps 
localized to ER 

























+ - 67±7 74±22 0.9 37±1 103±5 0.4 
More diffuse pattern 
localized to ERGIC 
 




Figure 1.  Age vs. estimated glomerular filtration rate (eGFR) in ADTKD-REN patients. A. All estimated 
glomerular filtration rate (eGFR) measurements for each group are included (signal group green, 
prosegment group red, mature group black).  A best-fit line is included for each group.  Patients in the 
mature group presented later in life and had normal kidney function at earliest measurement.  Patients 
in the signal and prosegment group often presented early in life, and eGFR was significantly decreased 
from the time of first measurement in most patients.  B. eGFR values in 13 children with longitudinal 
follow-up from the signal group. Each child is represented by a different color with a best-fit line, and 
the REN mutation is given in the legend.  Despite having low eGFR values at earliest measurement, 
kidney function remained stable until age 20 in most patients. 
 
Figure 2. End-stage kidney disease (ESKD) survival in ADTKD-REN individuals according to REN 
mutation group. This analysis included 111 individuals. An event was defined as starting dialysis or 
receiving a transplant. Censoring occurred if the individual had not reached ESKD by the end of the study 
period.  Patients in the mature group had a later age of onset of ESKD compared to the signal and 
prosegment groups (hazards ratio = 0.237, p=0.023). 
 
Figure 3.  End-stage kidney disease (ESKD) survival according to presence of anemia in childhood. This 
analysis included 111 ADTKD-REN individuals.  An event was defined as starting dialysis or receiving a 
transplant. Censoring occurred if the individual had not reached ESKD by the end of the study period.  A 





Figure 4.  Hemoglobin, hyperkalemia and acidemia in ADTKD-REN patients. White circles represent 
females and black circles represent males. A. Hemoglobin values according to age. For females, 
hemoglobin values were low throughout the period of measurement.  For males, hemoglobin values 
began to rise at age 20. B. Serum potassium values according to age.  Values remained consistent over 
time. C. Serum potassium according to estimated glomerular filtration rate (eGFR).  D. Serum 
bicarbonate values according to age.  There were many serum bicarbonate values  <24 mEq/l. 
 
Figure 5. ADTKD-REN treatment with fludrocortisone.   This figure includes 13 young patients in signal 
(n=11) and prosegment groups (n=2), mutations are listed in the legend.  The patient denoted with 
burgundy markers began fludrocortisone age 11, with an increase in eGFR that was sustained. The 
patient denoted with red markers started fludrocortisone at age 13. 
 
Figure 6.  In silico analysis of REN variants. (A) Preprorenin, a precursor of prorenin and renin, consists 
of : i) the signal peptide (SP) essential for targeting and insertion of the synthesized protein into the 
endoplasmic reticulum membrane, ii) the prosegment that determines the biosynthesis, cellular 
trafficking and enzymatic activity and iii) the mature enzymatically active renin that is formed upon the 
proteolytic cleavage of prorenin. Novel pathogenic mutations identified and characterized in this study 
are shown in red. Previously reported dominant mutations associated with ADTKD are shown in green. 
The p.S45N is considered nonpathogenic and is shown in blue.  Variants of unknown significance 
identified in African-American variants are shown in yellow. Epitope 288-377 denotes the protein 
segment recognized by the anti-preprorenin antibody used in this study.  The n, h and c regions 
respectively denote stretches of positively charged amino acids (n-region), hydrophobic amino acids (h-
region) essential for targeting and insertion of the signal peptide into ER membrane, and polar amino 
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acids (c-region), forming a recognition site for the signal peptidase that releases translocated 
preproprotein from its ER membrane-anchored signal peptide. (B) Amino acids conservation across 
mutated segments of REN in higher mammals. Asterisks (*) indicate amino acid residues that are 
absolutely conserved, a colon (:) indicates residues with strong conservation and a dot (.) indicate 
residues with weak conservation between species. (C) Computational prediction by the SignalP 4.1 
server of the impact of missense REN mutations located in the signal peptide on the conformation of the 
signal peptide cleavage site location (C-score) and on the sequence characteristics of the signal peptide 
(Y-score). SP denotes presence (YES/NO) of the signal peptidase cleavage site within the given sequence. 
The first 60 N-terminal amino acids of REN were used for this calculation. (D) Computational prediction 
by Mendelian Clinically Applicable Pathogenicity Score (M-CAP) of the pathogenicity of missense REN 
mutations located in the propeptide and mature renin.  
 
Figure 7. Structural topology and impact of prosegment and renin mutations. The crystal structure of 
prorenin (PDB ID 3VCM) was used for modelling. The prorenin segment (amino acid residues 24-66) and 
the renin core (amino acid residues 67-406) are colored in magenta and green, respectively. The location 
of mutated residues is shown in the full structural model using red spheres. The effects of each mutation 
are illustrated in detail at individual images. Mutated residues and their interactions are highlighted as 
sticks and dashed lines. The mutation p.R33W loses polar contacts with Q241 and D248. Possible 
compensatory interactions between the proximal two beta-sheets are highlighted as three dashed lines. 
These changes decrease affinity between prorenin and renin. The mutation p.M39K causes steric clashes 
and charge repulsion with K100, resulting in decreased affinity between prorenin and renin. The 
nonpathogenic mutation p.S45N changes the interaction network, with S45 interacting with S41, while 
N45 interacts with L137 and D139. These changes increase affinity due to a changed interaction 
network.  The mutation p.C325R disrupts a disulfide bridge (highlighted as sticks), and incorporation of 
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the arginine residue causes steric clashes (shown as red areas). The mutation p.I366Nresults in the loss 
of hydrophobic contacts (shown by red spheres) in the renin core.  
 
Figure 8. Transient expression and functional characterization of REN variants in Human Embryonic 
Kidney 293 cells. The wild type renin (WT); signal peptide, prosegment and mature renin mutations; 
African-American (AA_REN) variants and empty vector were analyzed. (A, B) Western blot analysis of (A) 
cell lysates and (B) culture media. Molecular weights of immuno-reactive proteins present in the WT 
lysates correspond with expected molecular weights of prorenin (47 kDa), preprorenin (45 kDa) and 
renin (43 kDa). (C, D) Immunoradiometric assay (IRMA) of prorenin and renin amounts in (C) cell 
lysates and (D) culture media employing a radio-labeled antibody that specifically recognizes active site 
of renin. The concentration of prorenin was calculated as the difference between the renin 
concentration measured before and after trypsin treatment, which activates renin by proteolytic 
cleavage of the prosegment from prorenin. Amounts of mutated renin (grey bars) and prorenin (black 
bars) were normalized to the amount of wild type renin.  The values represent means ± SD. 
Measurements were performed in three independent clones for each of the constructs. The individual 
measurements were carried out in triplicate. The statistical significance of the differences between the 
WT and renin variants protein amounts was tested by t test. *p < 0.05; **p > 0.01; ***p > 0.001; n.d. not 
done. (E, F)  Enzymatic activity of (E) mature renin secreted into culture media and (F) prorenin 
secreted into culture media. The values were normalized to the WT (100%) and represent means ± SD of 
relative fluorescent unit (RFU) generated by renin mediated cleavage of the 5-FAM and QXL520 
conjugated renin substrate. Measurements were performed in three independent clones for each of the 
constructs. The individual measurements were carried out in triplicate. The statistical significance of the 
differences between activity of the wild type renin (WT) and renin variants was tested by t test. *p < 
0.05; **p > 0.01; ***p > 0.001; n.d. not done.   
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Figure 9.Transient expression and intracellular localization of transiently expressed mutated 
preprorenin, prorenin and renin in Human Embryonic Kidney 293 cells. 
Preprorenin, prorenin and renin were detected using an antibody recognizing the epitope 288-317 of 
preprorenin and (9A) co-localized with a marker of endoplasmic reticulum intermediate compartment 
(ERGIC53); wild type protein was present in coarsely granular structures that were localized exclusively 
in the cytoplasm. Proteins with signal peptide mutations demonstrated either a very similar granular 
pattern (p.L16del) or intense diffuse cytoplasmic staining; (for detailed renin staining see Supplementary 
Figure S2). Proteins with prosegment mutations demonstrated a less distinct and more diffuse pattern 
that was localized mainly to ERGIC. The AA_REN variant p.P8A had similar staining pattern to the wild 
type. The AA_REN variant p.R33W demonstrated a less distinct and more diffuse pattern that was 
localized mainly to the ERGIC. Co-staining of renin with (B) protein disulphide isomerase (PDI), a marker 
of endoplasmic reticulum (ER) demonstrating localization of mature renin mutations in the ER. The 
degree of renin colocalization with selected markers is demonstrated by the fluorescent signal overlap 
coefficient values that ranging from 0-1. The resulting overlap coefficient values are presented as the 
pseudo color which scale is shown in corresponding lookup table. 
 
Figure 10. Pathophysiology of ADTKD-REN. (A) Wild type preprorenin is cotranslationally translocated 
into the ER. The signal sequence is cleaved during translocation, and nascent prorenin is glycosylated. 
Prorenin then transits through the ER-Golgi Intermediate Compartment (ERGIC), which monitors proper 
protein folding and detects aberrant protein forms. In the Golgi apparatus prorenin is both sorted to 
clear vesicles and constitutively secreted to proto-granules, where it is proteolytically processed to 
renin, which is later subjected to regulated secretion. (B) Mutations in the signal peptide prevent 
translocation across the ER membrane, and the preprorenin is aberrantly located in the cytoplasm. This 
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results in clinical renin deficiency and ER stress in renin producing cells. Mutations in the mature renin 
lead to retention of mutated protein in ER. This initiates ER stress similar to that seen in UMOD 
mutations and uromodulin retention in ADTKD-UMOD. Mutations in the prosegment introduce 
structural changes affecting protein biosynthesis, folding and travel along the secretory pathway causing 






Figure S1. Flow diagram of the ADTKD-REN International Cohort 
Figure S2. Representative family trees from 3 families with dominant REN mutations 
Figure S3. Intracellular localization of  transiently expressed mutated preprorenin, prorenin and renin in 
Human Embryonic Kidney 293 cells 
Figure S4. Localization of  transiently expressed mutated preprorenin, prorenin and renin in Golgi 
apparatus of Human Embryonic Kidney 293 cells  
Figure S5. Localization of  transiently expressed  mutated preprorenin, prorenin and renin in lysosomes 
of Human Embryonic Kidney 293 cells 
Figure S6. Colocalization of transiently expressed mutated preprorenin, prorenin and renin in ERGIC of 
Human Embryonic Kidney 293 cells 
Supplementary Methods 
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Figure S1. Flow diagram of the ADTKD-REN International Cohort. Twelve academic centers with an interest in ADTKD contributed 68 patients from 14 
families previously not reported. Wake Forest School of Medicine-Charles University contributed six patients from four families previously not reported and 
18 patients from four families published (S1-S2). Literature review yielded five papers describing 19 patients from five families (S3-S7). 












Figure S2. Representative family trees from three families with dominant REN mutations.  Clear symbols represent clinically unaffected and filled symbols 
represent clinically affected.  Individuals with 1 asterisk (*) underwent genetic testing and were negative. Individuals with 2 asterisks (**) underwent genetic 





















Figure S3. Intracellular localization of  transiently expressed mutated preprorenin, prorenin and renin 
in Human Embryonic Kidney 293 cells. Immunofluorescence detection with an antibody recognizing the 
epitope 288-317 of preprorenin demonstrates that the wild type protein is present in coarsely granular 
structures that are localized exclusively in the cytoplasm. Proteins with the mutations in the signal 
peptide demonstrate either a very similar granular pattern (pL16del) or intense diffuse cytoplasmic 


































Figure S4. Localization of  transiently expressed mutated preprorenin, prorenin and renin in Golgi 
apparatus of Human Embryonic Kidney 293 cells.  Immunofluorescent costaining of renin (REN) with an 
antibody recognizing the epitope 288-317 of preprorenin and Golgi apparatus with mouse anti-GM130 
(GM130) showing limited localization of wild type and mutant proteins in Golgi.  The degree of renin 
colocalization with selected marker is demonstrated by the fluorescent signal overlap coefficient values 
that ranging from 0-1. The resulting overlap coefficient values are presented as the pseudo color which 
scale is shown in corresponding lookup table. 
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Figure S5. Localization of  transiently expressed  mutated preprorenin, prorenin and renin in 
lysosomes of Human Embryonic Kidney 293 cells. Immunofluorescent costaining of renin (REN) with an 
antibody recognizing the epitope 288-317 of preprorenin and lysosome with  Mouse anti-LAMP2 
showing localization of the wild type protein, the protein with signal peptide mutation L16del and 
proteins with prosegment mutations (T26I, M39K and S45N) in lysosomes. Proteins with other signal 
peptide mutations (L13Q and L16P) and protein with mutations in the mature renin (C325R) did not 
localize to lysosomes. The degree of renin colocalization with selected marker is demonstrated by the 
fluorescent signal overlap coefficient values that ranging from 0-1. The resulting overlap coefficient 
values are presented as the pseudo color which scale is shown in corresponding lookup table. 
  













Figure S6. Colocalization of transiently expressed mutated preprorenin, prorenin and renin in ERGIC of 
Human Embryonic Kidney 293 cells. The Pearson's correlation coefficients of the degree of 
colocalization of wild type and mutated renin and ERGIC were calculated for 10 transfected cells in the 
Huygens Professional Software; (y-axis).  +1 represents perfect correlation, 0.5 random colocalization 
and 0 no correlation. Representative immunofluorescence staining is shown in Figure 9. 
  




Transient expression of preprorenin in HEK293 cells 
8 x 10
5
 HEK 293 cells were seeded on a 6-well plate and grown for 24 hours in DMEM with 10% FCS and 
1 mM HEPES (pH 7.31) containing DMEM/F12 media (Gibco) supplemented with 10% fetal calf serum 
(Gibco) and penicillin / streptomycin at 100 U/ml and 100 μg/ml, respectively, at 37 °C in a 5% 
CO2 atmosphere (Sigma). After 24 hours, cells were transfected with Lipofectamine TM2000 with 4µg of 
appropriate cDNA constructs and grown either in serum-free medium without phenol red (for western 
blot and enzymatic activity analysis) or fully supplemented medium with phenol red (for IRMA analysis). 
At 24 hours after transfection, 1 mL media from each type was collected.  Cells were mechanically 
harvested either by PBS1x for quantitative analysis of synthesized renin and prorenin (IRMA method) or 
lysed by lysis buffer with Protease Inhibitor Cocktail followed by qualitative study (western blot). For 
IRMA analysis, the amount of renin and prorenin were normalized to total protein concentration in 
lysates. Total protein concentration was determined using Bradford solution according to the 
manufacturer protocol (BioRad).  Absorbance was measured by the Infinite 200 Pro reader (Tecan, 
Austria, GmbH) at 595 nm. 
 
Western blot analysis 
Cells cultured in FBS and phenol red-free medium were harvested to PBS and pelleted at 800g/7 min/RT. 
Pellets were resuspended in SDS-PAGE sample buffer (50 mM Tris HCl, 50 mM DTT, 2% SDS, pH 6,8) with 
Protease Inhibitor Cocktail (Sigma, Prague, Czech Republic) added in a 100:1 ratio and incubated on ice 
for 3 hours. Lysates were sonicated 3 times for 10 sec with an Ultrasonic Homogenizer 4710 (Cole-
Palmer Instruments, Vernon Hills, IL, USA) equipped with cup horn filled with ice cold water, denatured 
at 100°C/5 min, cooled on ice and stored at -20°C. The protein concentration in lysates was measured by 





 Infrared Spectrometer (Merck Millipore, Billarica, MA, USA), according to manufacturer’s 
instructions. 
For the secreted renin analysis, FBS and phenol red-free cell culture media were aspirated, mixed with a 
Protease inhibitor cocktail in 100:1 ratio and successively cleared at 800g/7 min and 15000g/5 min at RT. 
Supernatants were concentrated on Amicon
®
 Ultra – 0.5mL Centrifugal Filters 10K (Merck Millipore, 
Tullagreen, Ireland) to minimal volume (about 20 µl) according to manufacturer’s instructions. 
Concentrated media were stored at -20°C.  
 
Volumes of lysates and media equivalent to 15 µg of proteins and 250000 cells, respectively, were mixed 
with 6X SDS-PAGE sample buffer (350 mM Tris Base, 10% SDS, 6% BME, 30% glycerol, 0,012% BPB, pH 
6,8) in 0,2 mL tubes, denatured at 100˚C/5 minutes and resolved on 4% stacking and 10% separating gel 
at 75 V and 150 V, respectively, in MightySmall II SE260 or SE640apparatus (Hoefer, San Francisco, CA, 
USA). Proteins were then transferred to methanol-activated PVDF membrane in semi-dry blotting 
apparatus PHERO-Multiblot (Biotec-Ficher, Reiskirchen, Germany) at 0.6 mA/cm2 for 60 minutes. 
Membrane was blocked in phosphate-buffered saline with 0.1% Tween 20 (PBST) and 5% BSA and 
probed with rabbit preprorenin (288-317) diluted 1:3000 in PBST with 0.1% BSA followed by HRP-
conjugated Goat anti-Rabbit IgG (H+L) secondary antibody (Thermo Fisher Scientific, Prague, Czech 
Republic) at 1:10,000 dilution.  
 
Membranes were incubated with Clarity™ Western ECL Substrate (Bio-Rad, Prague, Czech Republic) 
according to manufacturer’s instructions. Signal was captured on CP-BU Medical X-ray blue film (Agfa) 
developed by Fomadent solution set (Foma Bohemia, Tisice-Chrast, Czech Republic). The tubulin protein 
was visualized by incubation with Mouse anti-Acetylated tubulin (T6793, Sigma Aldrich) at dilution 
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1:3000 in 0.1% BSA and 0.1% Tween 20 in PBS for 1 hour at RT, followed by incubation with Goat anti-
Mouse  HRP (Pierce) under conditions and using detection as described above. 
 
 
Quantitative analysis of renin and prorenin by immunoradiometric assay (IRMA) 
Cell lysate was prepared as described above. The medium was centrifuged at 15,000 x g for 10 min, and 
the resulting supernatant was mixed with protease inhibitor cocktail in ratio 100:1 (vol/vol). 
For renin determination, 50 µl of the medium and 5 µl of the lysate were diluted to a final volume of 
200µl with PBS. For trypsin-activated total renin and prorenin amount, 5µl of medium and 2.5µl of lysate 
were incubated at 37°C for 30 min in a 50µl PBS reaction containing 100 µg and 400 µg of trypsin, 
respectively. The reactions were stopped by 1µl of 10 mg/mL trypsin inhibitor (PMSF, Roche, Prague, 
Czech Republic) and diluted to a final volume of 200 µl with PBS.  
Ten µl of the resulting mixtures was mixed with 290 µl of PBS and 100 µl of the anti-hRenin (I-125) 
reagent (Renin III Generation Kit, CISBIO Bioassays, France), and the renin amount was measured 
according to manufacturer’s instructions.  
 
Measurement of the enzymatic activity of renin secreted into the culture media  
We measured the enzymatic activity of renin before and after cleavage of the propeptide region and of 
prorenin secreted into culture media after transient expression of renin variants and wild type renin. 
Seeding, maintaining and transfection were performed as described above. Twenty four hours after 
lipofection, the medium was collected and divided into 2 tubes. Trypsin / EDTA 1x (volume ratio medium 
: T/E = 1: 3) was added to one tube and incubated 30 min at 37°C for cleavage of prosegment from 
prorenin. The trypsin reaction was stopped by adding of 2,6 µL of 50mM PMSF (Roche) and incubated 
for 15 min at room temperature. 100µL media before and after trypsin incubation were placed into a 
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96-well plate and 50µL of 100x diluted renin substrate conjugated with 5-FAM and QXL520 was added 
(part of SensoLyte 520 Renin Assay Kit, AnaSpec, San Jose, CA). The fluorescent signal was monitored at 
528 nm every 15 min for 3 hr at 37°C on an Infinite 2000Pro microplate reader (Tecan, Austria). Each 
sample either before or after trypsin activation was measured in triplicate. For graph construction, we 
used values after 75 minutes from the start of measurement, which was the time of maximum signal in 




 HEK293 cells were plated on polysinated glass coverslips for 24 hours and transiently 
transfected by LipofectamineTM3000 with 1µg plasmid DNA of wt renin, L16del, C20R, L13Q, L16P, 
W17R, T26I, M39K, C325R, I366N, P8A, R33W, respectively according to the manufacturer’s protocol. 24 
hours after lipofection, cells were quickly washed with PBS1x and fixed with cold 100% methanol. After 
fixing, cells were washed three times in PBS 1x and proteins were blocked for 30 min at room 
temperature in PBS with 5% FCS. Cells were incubated over night at 4°C with rabbit primary antibody 
anti-human preprorenin 288-317 (Yanaihara) at a dilution of 1:50 or mouse anti-PDI (Enzo) at a dilution 
1:200 or mouse anti-ERGIC (Acris) at a dilution 1:200. For colocalization with Golgi Apparatus we used 
mouse anti-GM130 (ab 169276, Abcam) at a dilution of 1:300. For colocalization with lysosomes we 
used mouse anti-LAMP2 (H4B4) (ab 25631, Abcam) at a dilution of 1:500. Cells were washed five times 
in PBS 1x and incubated with donkey anti-rabbit Alexa Fluor 555 and goat anti-mouse Alexa Fluor 488 
(Invitrogen) at dilution 1:1000. All antibodies were diluted in PBS 1x with 5% FCS and 0.05% Tween 20. 
Cells were washed four times and mounted into Antifade with DAPI (Invitrogen) for confocal imaging.   
 
Image acquisition and analysis 
Prepared slides were analyzed by confocal microscopy. XYZ images were sampled according to Nyquist 
criterion using a LeicaSP8X laser scanning confocal microscope, HC PL APO objective (63x, N.A. 1.40), 
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405, 488 and 543 laser lines. Images were restored using a classic maximum likelihood restoration 
algorithm in the Huygens Professional Software (SVI, Hilversum, The Netherlands). The colocalization 
maps employing single pixel overlap coefficient values ranging from 0-1, were created and the 
colocalization coefficients were calculated in the Huygens Professional Software. The resulting overlap 
coefficient values are presented as the pseudo color which scale is shown in corresponding lookup 
tables (LUT). Approximately ten cells per variant were analyzed. 
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